CoChat
Sign Up
Cited by 51Cervical Cancer and HPV ResearchReproductive tract infections researchWomen's cancer prevention and management

Prevalence of human papillomavirus genotypes and precancerous cervical lesions in a screening population in the Republic of Korea, 2014–2016

Open access
Ouh, Yung-Taek, Min, Kyung-Jin, Cho, Hyun Woong, Ki, Moran, Oh, Jin-Kyoung, Shin, Sang Yop, Hong, Jin Hwa, Lee, Jae-Kwan·2018·Journal of Gynecologic Oncology
DOI 10.3802/jgo.2018.29.e14PMC PMC5709524
Open this paper in CoChat — free accountOpen PDF

Abstract

OBJECTIVE: Knowledge regarding the prevalence and distribution of human papillomavirus (HPV) genotyping in healthy women is important in establishing strategies for cervical cancer screening and HPV vaccination. METHODS: A total of 18,170 women who visited a Korean Medical Institute for health check-ups were recruited retrospectively; they underwent HPV genotyping and conventional cervical cytology. An HPV DNA test was performed using the Anyplex™ II HPV 28 detection system (Seegene) or HPV Liquid Bead Microarray (Osang Healthcare). The distribution of HPV genotypes was assessed according to cervical cytology and age. RESULTS: HPV was detected in 3,037 (16.71%) of the 18,170 women enrolled, and 2,268 (12.48%) were positive for high-risk (HR) HPV. In total, HPV 53 (9.69% of all detected HPV viruses) was the most common type; HPV 58 (7.90%) and 52 (7.81%) were also common. HPV 54 (6.99%) was common in low-risk subjects. Overall and in the normal cytology group, the most common HPV genotype was HPV 53, whereas HPV 58 was more common in women who had atypical squamous cells of undetermined significance or low-grade squamous intraepithelial neoplasia cervical cytology. In addition, HPV 16 was the most common type in cases with high-grade squamous intraepithelial neoplasia (HSIL)/atypical squamous cells-cannot exclude HSIL. Among women with normal cytology, 76 of 231 (32.9%) women under 24 years of age were positive for HR HPV, whereas 84 of 852 (9.9%) women aged 55-59 years were positive. CONCLUSION: HPV 53 was the most prevalent genotype in healthy women. Distribution of HPV genotypes varied with cervical cytology and age. Our study provides important baseline data for the recently implemented national HPV vaccination program.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3802/jgo.2018.29.e14

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Anyplex is widely used for cervical cancer screening in South Korea, including at the authors' hospital.

    “Anyplex is also widely used for cervical cancer screening in South Korea, including at our hospital [30–32].”

    From Comparison of Seegene Anyplex II HPV28 assay with BD Onclarity HPV assay for human papillomavirus genotyping (2022) · cites this paper as [32]

    The Methods (HPV DNA testing; page unavailable) report that Anyplex was used on 7,331 samples at a Korean screening organization in 2016. This establishes use in a South Korean screening setting, but not that Anyplex was widely used nationwide or used at the citing authors’ hospital. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 30

  1. [1]Jung KW Won YJ Oh CM Kong HJ Lee DH Lee KH Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2014 Cancer Res Treat 2017 49 292 305 28279062 PMC5398380
  2. [2]Min KJ Lee YJ Suh M Yoo CW Lim MC Choi J The Korean guideline for cervical cancer screening J Gynecol Oncol 2015 26 232 239 26197860 PMC4510341
  3. [3]Huh WK Ault KA Chelmow D Davey DD Goulart RA Garcia FA Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance Gynecol Oncol 2015 136 178 182 25579107
  4. [4]Remmerbach TW Brinckmann UG Hemprich A Chekol M Kühndel K Liebert UG PCR detection of human papillomavirus of the mucosa: comparison between MY09/11 and GP5+/6+ primer sets J Clin Virol 2004 30 302 308 15163418
  5. [5]Campos NG Mvundura M Jeronimo J Holme F Vodicka E Kim JJ Cost-effectiveness of HPV-based cervical cancer screening in the public health system in Nicaragua BMJ Open 2017 7 e015048 PMC5623348 28619772
  6. [6]Tantitamit T Termrungruanglert W Khemapech N Havanond P A model approach for assessing the benefits of HPV testing against cytology in screening for cervical cancer precursors in Thailand Asian Pac J Cancer Prev 2017 18 1271 1275 28610413 PMC5555534
  7. [7]Armstrong EP Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types J Manag Care Pharm 2010 16 217 230 20331326 PMC10437588
  8. [8]FUTURE I/II Study Group Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial BMJ 2010 341 c3493 20647284 PMC2907480
  9. [9]Cuzick J Gardasil 9 joins the fight against cervix cancer Expert Rev Vaccines 2015 14 1047 1049 26028344
  10. [10]Joura EA Giuliano AR Iversen OE Bouchard C Mao C Mehlsen J A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women N Engl J Med 2015 372 711 723 25693011
  11. [11]Muñoz N Kjaer SK Sigurdsson K Iversen OE Hernandez-Avila M Wheeler CM Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women J Natl Cancer Inst 2010 102 325 339 20139221
  12. [12]Forman D de Martel C Lacey CJ Soerjomataram I Lortet-Tieulent J Bruni L Global burden of human papillomavirus and related diseases Vaccine 2012 30 Suppl 5 F12 F23 23199955
  13. [13]de Martel C Plummer M Vignat J Franceschi S Worldwide burden of cancer attributable to HPV by site, country and HPV type Int J Cancer 2017 141 664 670 28369882 PMC5520228
  14. [14]Clifford GM Rana RK Franceschi S Smith JS Gough G Pimenta JM Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer Cancer Epidemiol Biomarkers Prev 2005 14 1157 1164 15894666
  15. [15]Monsonego J Zerat L Syrjänen K Zerat JC Smith JS Halfon P Prevalence of genotype-specific HPV infection among women in France: implications for screening and vaccination Gynecol Obstet Fertil 2013 41 305 313 23647817
  16. [16]Kim MJ Kim JJ Kim S Type-specific prevalence of high-risk human papillomavirus by cervical cytology and age: data from the health check-ups of 7,014 Korean women Obstet Gynecol Sci 2013 56 110 120 24327989 PMC3784093
  17. [17]Solomon D Davey D Kurman R Moriarty A O'Connor D Prey M The 2001 Bethesda system: terminology for reporting results of cervical cytology JAMA 2002 287 2114 2119 11966386
  18. [18]Kwon MJ Roh KH Park H Woo HY Comparison of the Anyplex II HPV28 assay with the Hybrid Capture 2 assay for the detection of HPV infection J Clin Virol 2014 59 246 249 24568964
  19. [19]Hang D Jia M Ma H Zhou J Feng X Lyu Z Independent prognostic role of human papillomavirus genotype in cervical cancer BMC Infect Dis 2017 17 391 28583086 PMC5460478
  20. [20]de Sanjose S Quint WG Alemany L Geraets DT Klaustermeier JE Lloveras B Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study Lancet Oncol 2010 11 1048 1056 20952254
  21. [21]Oh JK Alemany L Suh JI Rha SH Muñoz N Bosch FX Type-specific human papillomavirus distribution in invasive cervical cancer in Korea, 1958–2004 Asian Pac J Cancer Prev 2010 11 993 1000 21133613
  22. [22]So KA Hong JH Lee JK Human papillomavirus prevalence and type distribution among 968 women in South Korea J Cancer Prev 2016 21 104 109 27390739 PMC4933434
  23. [23]Krashias G Koptides D Christodoulou C HPV prevalence and type distribution in Cypriot women with cervical cytological abnormalities BMC Infect Dis 2017 17 346 28511636 PMC5434522
  24. [24]Kjær SK Munk C Junge J Iftner T Carcinogenic HPV prevalence and age-specific type distribution in 40,382 women with normal cervical cytology, ASCUS/LSIL, HSIL, or cervical cancer: what is the potential for prevention? Cancer Causes Control 2014 25 179 189 24242002
  25. [25]Rhee JE Shin MY Kim CM Kee HY Chung JK Min SK Prevalence of human papillomavirus infection and genotype distribution among high-risk Korean women for prospecting the strategy of vaccine development Virol J 2010 7 201 20738861 PMC2936902
  26. [26]Bae JH Lee SJ Kim CJ Hur SY Park YG Lee WC Human papillomavirus (HPV) type distribution in Korean women: a meta-analysis J Microbiol Biotechnol 2008 18 788 794 18467878
  27. [27]Lee HS Kim KM Kim SM Choi YD Nam JH Park CS Human papillomavirus genotyping using HPV DNA chip analysis in Korean women Int J Gynecol Cancer 2007 17 497 501 17316356
  28. [28]Shin HR Franceschi S Vaccarella S Roh JW Ju YH Oh JK Prevalence and determinants of genital infection with papillomavirus, in female and male university students in Busan, South Korea J Infect Dis 2004 190 468 476 15243918
  29. [29]Zappacosta R Lattanzio G Viola P Ianieri MM Gatta DM Rosini S A very rare case of HPV-53-related cervical cancer, in a 79-year-old woman with a previous history of negative Pap cytology Clin Interv Aging 2014 9 683 688 24790420 PMC3998847
  30. [30]Song ES Lee HJ Hwang TS Clinical efficacy of human papillomavirus DNA detection in urine from patients with various cervical lesions J Korean Med Sci 2007 22 99 104 17297259 PMC2693577

Cited by

Sorted by citations

Authors
Ouh, Y.-T., Min, K.-J., Cho, H. W., Ki, M., Oh, J.-K., Shin, S. Y., Hong, J. H., & Lee, J.-K.
Affiliations
  • Korea University Guro Hospital (KR)
  • Korea University Ansan Hospital (KR)
  • National Cancer Center (KR)
  • Korea Medical Institute (KR)
Corresponding author
Lee, Jae-Kwan
ORCID
Venue
Journal of Gynecologic Oncology
Publisher
XMLink
Published
2018
Volume
29
Issue
1
Pages
e14-e14
ISSN
  • 2005-0380 (ISSN-L)
  • 2005-0399
DOI
10.3802/jgo.2018.29.e14
PMC
PMC5709524
OpenAlex
W2769853003
Cited by
51
References
3
Citations by year
2026: 5 · 2025: 7 · 2024: 7 · 2023: 7 · 2022: 7 · 2021: 8 · 2020: 3 · 2019: 3 · 2018: 4
FWCI
2.14
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Gynecologic Oncology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Korea Centers for Disease Control & Prevention (2016E3200600)
Topics
  • Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
  • Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Women's cancer prevention and management
Keywords
human papillomavirus, HPV genotypes, HPV prevalence, cervical cancer screening, cervical precancerous lesions, HPV53, HPV58, HPV16, high-risk HPV, HPV vaccination, cervical cytology, age distribution, healthy women, Korea
MeSH terms
Adolescent, Adult, Aged, Aged, 80 and over, Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, DNA, Viral, Female, Genotype, Humans, Mass Screening, Middle Aged, Precancerous Conditions, Retrospective Studies, Vaginal Smears, Virology, Prevalence, Papillomaviridae, Papillomavirus Infections, Early Detection of Cancer, Young Adult, Republic of Korea, Molecular Typing, Human Papillomavirus DNA Tests, Atypical Squamous Cells of the Cervix, Squamous Intraepithelial Lesions of the Cervix

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review